The First Human Trial to Reverse Cellular Aging Has Begun - And Medicine May Never Be the Same

On June 9, 2026, the first human received an experimental treatment to reverse ageing in eye cells. The therapy, known as ER-100, is designed to restore youthful function to damaged optic nerve cells in people with conditions such as open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), diseases that can lead to irreversible blindness.

If successful, ER-100 could mark the beginning of an entirely new era in medicine, one where doctors do not merely treat diseases of aging but begin addressing aging biology itself.

In January 2026, biotechnology company Life Biosciences announced FDA clearance for ER-100, which was developed based on research led by Harvard geneticist Dr David Sinclair. Aging has long been viewed as an inevitable biological deterioration, the gradual breakdown of cells, tissues, and organs. Sinclair's research proposes something more radical. His theory suggests that aging may be driven not only by cumulative damage, but also by so-called loss of epigenetic information.

Think of your DNA as hardware. Every cell in your body contains the same genetic code, yet a skin cell knows it is skin, a liver cell behaves like a liver, and a neuron functions as a part of the brain. This is because of the epigenome: biological software that tells genes when to switch on and off. Over time, stress, inflammation, DNA damage, toxins, poor sleep, and everyday life disrupt this software. Cells begin to lose clarity about their role. They're not permanently damaged, but, in a sense, they begin to forget who they are.

In a 2023 study published in Cell, Sinclair’s team accelerated epigenetic damage in mice by triggering controlled DNA breaks that mimic cumulative aging. The animals rapidly developed signs of aging: frailty, tissue dysfunction, and cognitive decline. More strikingly, some changes were partially reversed when researchers activated cellular reprogramming factors.

The implication was profound: If aging partly reflects distorted instructions, perhaps cells can be reminded how to function more youthfully again.

Why Scientists Are Starting With the Eye

The first human trials target the optic nerve for practical reasons: the eye is self-contained, easier to monitor, and safer for early testing than treating the entire body. Researchers can directly measure whether visual function improves.

The treatment uses a controlled form of partial epigenetic reprogramming involving three of the so-called Yamanaka factors, discovered by Japanese stem cell biologist and a Nobel Prize laureate, Shinya Yamanaka. These genes are known to restore aspects of cellular youthfulness without fully erasing cell identity. In earlier animal models, this approach restored damaged optic nerve function and reversed vision loss. Now it is being tested in humans.

If successful, researchers envision future applications across neurodegenerative disease, organ repair, and muscle degeneration. The goal is not longer life for its own sake, but more functional years, as the global population over 60 is expected to exceed 2 billion by 2050, and aging remains the single greatest risk factor for dementia, heart disease, and most cancers.

Gene therapy is expensive. Early rejuvenation treatments may cost tens or hundreds of thousands of pounds. That's why many researchers are searching for a simpler approach: molecules that replicate some of the rejuvenating effects without genetic intervention. Machine learning models can rapidly screen thousands of compounds against biological aging pathways, dramatically accelerating that search. This is also an area I work on as a biomedical engineering researcher, using AI to understand biomarker patterns associated with aging and to help identify candidate molecules for healthier aging. What begins as an advanced biological procedure could one day become accessible medicine.

We are not there yet. But the direction is set.

What You Can Do Right Now

The strongest evidence we currently have for slowing biological aging still comes from surprisingly ordinary habits. Stable blood sugar, healthy body composition, regular aerobic exercise combined with resistance training, adequate sleep, and a diet based on whole foods rather than ultra-processed ones remain the most accessible tools we have for shifting our biological age in the right direction. The future of longevity may be high-tech. The present is still stubbornly low-tech. And tracking your own biomarkers, blood pressure, glucose, cholesterol, and inflammatory markers, matters more than most people realise.

For years, the idea of reversing aging lived mostly in TED talks, speculative books, and billionaire fantasies.

This feels different.

A clinical trial does not guarantee success. Most scientific breakthroughs fail. Unexpected side effects and limitations may still emerge. That is how science works. But something important has changed.

The question is no longer "Could cellular rejuvenation ever become possible?" It has become "How far can it go?"